Cemtrex, Inc. (CETX) Is At $2.58 Formed Wedge; Corcept Therapeutics (CORT) Sellers Increased By 27.22% Their Shorts

Corcept Therapeutics Incorporated (NASDAQ:CORT) had an increase of 27.22% in short interest. CORT’s SI was 9.48M shares in January as released by FINRA. Its up 27.22% from 7.45 million shares previously. With 1.32M avg volume, 7 days are for Corcept Therapeutics Incorporated (NASDAQ:CORT)’s short sellers to cover CORT’s short positions. The SI to Corcept Therapeutics Incorporated’s float is 10.44%. The stock increased 4.36% or $0.87 during the last trading session, reaching $20.81. About 1.47M shares traded. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 124.81% since January 11, 2017 and is uptrending. It has outperformed by 108.11% the S&P500.

Cemtrex, Inc. (CETX) formed wedge down with $2.43 target or 6.00% below today’s $2.58 share price. Cemtrex, Inc. (CETX) has $27.23M valuation. The stock increased 0.78% or $0.02 during the last trading session, reaching $2.58. About 72,429 shares traded. Cemtrex, Inc. (NASDAQ:CETX) has risen 80.19% since January 11, 2017 and is uptrending. It has outperformed by 63.49% the S&P500.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company has market cap of $2.38 billion. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It has a 71.76 P/E ratio. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

Investors sentiment decreased to 1.96 in 2017 Q3. Its down 0.47, from 2.43 in 2017Q2. It fall, as 13 investors sold Corcept Therapeutics Incorporated shares while 39 reduced holdings. 47 funds opened positions while 55 raised stakes. 71.96 million shares or 6.38% more from 67.64 million shares in 2017Q2 were reported. Blackrock Inc holds 0.01% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 7.76M shares. Geode Management Ltd Llc has 0.01% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 962,957 shares. Essex Invest Management Lc owns 304,101 shares. James Invest Research holds 0.08% or 117,400 shares in its portfolio. Principal Group Inc owns 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 38,692 shares. Sanctuary Wealth Advisors Ltd Com accumulated 465 shares or 0.01% of the stock. Citadel Advsr Limited Co has invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Paloma Partners Mngmt stated it has 62,439 shares. American Intll Group Inc, a New York-based fund reported 61,110 shares. Citigroup stated it has 244,818 shares or 0% of all its holdings. Ameritas Prns Inc holds 8,001 shares. The Illinois-based Northern Tru has invested 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Blair William & Il holds 27,000 shares. First Quadrant Limited Partnership Ca holds 2,115 shares. Qs Invsts Ltd Limited Liability Company has invested 0.03% in Corcept Therapeutics Incorporated (NASDAQ:CORT).

Since December 8, 2017, it had 0 insider buys, and 1 insider sale for $133,776 activity. Shares for $133,776 were sold by FISHMAN ROBERT S on Friday, December 8.

Among 4 analysts covering Corcept Therapeutics (NASDAQ:CORT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corcept Therapeutics had 7 analyst reports since February 2, 2017 according to SRatingsIntel. As per Thursday, August 24, the company rating was maintained by Piper Jaffray. Piper Jaffray maintained it with “Buy” rating and $24.0 target in Friday, September 8 report. Piper Jaffray maintained the stock with “Buy” rating in Wednesday, October 11 report. The company was initiated on Thursday, February 2 by Ladenburg Thalmann. Stifel Nicolaus maintained Corcept Therapeutics Incorporated (NASDAQ:CORT) rating on Friday, November 3. Stifel Nicolaus has “Buy” rating and $25.0 target.